YUHSpace

BROWSE

Export
0 2

Cited 0 times in

Cited 0 times in

What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?

DC Field Value Language
dc.contributor.author심효섭-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.date.accessioned2025-10-15T01:31:32Z-
dc.date.available2025-10-15T01:31:32Z-
dc.date.issued2025-09-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/207396-
dc.description.abstractSmall cell lung cancer ; Large cell neuroendocrine carcinoma ; Diagnostics ; Novel therapies-
dc.description.statementOfResponsibilityhttps://www.sciencedirect.com/science/article/pii/S2666364325000888-
dc.languageEnglish-
dc.publisherElsevier Inc.-
dc.relation.isPartOfJTO Clinical and Research Reports-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESH1-
dc.titleWhat Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학교실)-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorJoo Sung Gabriel Shim-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorJunko Tanizaki-
dc.contributor.googleauthorJorn Nutzinger-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorRoss A. Soo MBBS-
dc.identifier.doiSCLC is a high-grade neuroendocrine malignancy associated with poor prognosis, comprising 15% of lung cancer cases globally. Advances in genetic profiling have revealed that SCLC is a molecularly heterogeneous disease, categorized into subtypes such as SCLC-A, SCLC-N, SCLC-P, and SCLC-I, on the basis of their neuroendocrine and immune-related characteristics. This heterogeneity underscores the need for tailored therapeutic strategies. Large cell neuroendocrine carcinoma (LCNEC) shares histologic and molecular similarities with SCLC but remains a distinct entity. LCNEC is categorized into two major subtypes: Type I, characterized by STK11 and KEAP1 mutations and a neuroendocrine phenotype, and Type II, defined by TP53 and RB1 alterations with higher proliferative indices. LCNEC's rarity and molecular diversity present challenges for standardized treatment, further highlighting the need for comparative research with SCLC. In this review, we highlight the genetic and clinicopathologic features of SCLC and LCNEC. Furthermore, we discuss emerging therapeutics and future directions in the treatment of SCLC and LCNEC.-
dc.contributor.localIdA02219-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ04164-
dc.identifier.eissn2666-3643-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.affiliatedAuthor심효섭-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume6-
dc.citation.number9-
dc.citation.startPage100871-
dc.identifier.bibliographicCitationJTO Clinical and Research Reports, Vol.6(9) : 100871, 2025-09-
dc.identifier.articleno10.1016/j.jtocrr.2025.100871-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links